The growing prevalence of hyperuricemia with the increase in age is expected to be the major driving factor for the growth of the xanthine oxidase inhibitors market over the forecast period. Lifestyle ...
TipRanks on MSN
XORTX leans into genetic breakthroughs in gout as it reshapes board and advances oxypurinol
XORTX Therapeutics Inc ( ($TSE:XRTX) ) has shared an announcement. XORTX Therapeutics highlighted newly published, large-scale genetic research ...
Micot (Suzhou) Technology Co. Ltd. has disclosed xanthine derivatives reported to be useful for the treatment of hypertension and asthma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback